![]() ![]() VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. The Big Five: Fundamental Ratios That You Should Evaluate.10 Mistakes You Should Avoid While Investing - Invest Smart with ShareIndia.5 Lessons Every Successful Investor Has Learned - And You Should Too!.Understanding Open Interest and It's Importance in Trading!.Trading Psychology - Mastering Emotions, Biases and Common Traps.Top Trading Strategies That You Can Start With Today.Short Term Trading Strategies for Beginners.Understanding The Basics To Get Started with Mutual Funds Investing.10 Reasons You Should Invest in Mutual Funds.How To Use Moving Averages To Buy Stocks?.Which Stocks Should I Pick For Intraday Trading?.Intraday Vs Positional Trading: Know The Difference.Is investing in gold a good idea during geopolitical tensions?.All You Need to Know About Investing in Gold in India.All You Need To Know About Sovereign Gold Bonds (SGB).Understanding Algo Trading And Its Future In Retail Investment.Initial Public Offerings (IPO) vs Follow On Public Offer (FPO).Understanding Draft Red Herring Prospectus.Should You Invest in IPO? Factors to Consider for Smart Investing.What is Inactive Demat Account and How Should You Monitor it?.Understand the Account Maintenance Charges for Demat Account.Learn About Collateral Amount in Demat Account.A Guide on How to Download Demat Holding Statement.Know About the Minimum Amount Requirement to Open a Demat Account.Louis to conduct a Phase 1b/2a clinical trial of SYN-004. ![]() It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center and a clinical trial agreement with Washington University School of Medicine in St. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics SYN-005 for the prevention and treatment of pertussis and VCN-11 to treat cancer. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Etsy Stock: Crafty Bargain or Piece of Junk?.Solo Brands May Remind Investors Why Cash is King.FuelCell Energy Gains Traction, Shares Surge.How to Buy High Yielding Dividend Stocks.Can Investors Trust Consumers to Lift American Outdoor Brands?.Three Staples Stocks With Double-Digit Upside Ahead.2 Offshore Drilling Stocks Set to Extract Big Profits.NVIDIA Stock Confirms Reversal Headed Higher?.Has Rivian Stock Reached a Buyable Bottom?.Rocket Lab Stock Could Go to the Moon, Patience Required.The Trader's Guide to Equities Research.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |